U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Drip More LLC - 548401 - 07/31/2018
  1. Warning Letters

CLOSEOUT LETTER

Drip More LLC MARCS-CMS 548401 —

Recipient:
Drip More LLC

United States

Issuing Office:

United States

   

Department of Health and Human Services logo

  
 
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring, MD 20993 

 

July 31, 2018
 
VIA UPS and Electronic Mail
 
Brian Bereber
Drip More LLC
1110 Palmyrita Ave Ste 120
Riverside, CA 92507
dripmore@gmail.com
 
RE: Warning Letter issued to Drip More LLC(RW1800843)
 
Dear Brian Bereber:
 
On May 1, 2018, the United States Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Candy King Batch and Candy King Sour Worms e-liquid products are misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your Candy King Batch and Candy King Sour Worms e-liquids are misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the products to imitate food products, particularly ones that are marketed toward, and/or appealing to, children. 
 
On May 11, 2018, June 7, 2018, June 8, 2018, June 21, 2018, and July 17, 2018, you sent FDA a response to the Warning Letter, and we held teleconferences on June 7, 2018 and July 17, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violations identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violations identified in the Warning Letter. We note that you may have other tobacco products with labeling and/or advertising that causes the product to be misbranded for similar reasons to those discussed above. You are responsible for taking any necessary actions to bring your tobacco products into compliance with the requirements of the law.
 
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.
 
Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov.
 
 
Sincerely,
/S/ 
Ele Ibarra-Pratt
Division Director
Office of Compliance and Enforcement
Center for Tobacco Products
 
 
VIA UPS and Electronic Mail
 
cc:
 
Azim Chowdhury
Keller and Heckman LLP
1001 G Street NW
Washington, DC 20001
chowdhury@khlaw.com
 
Brian Bereber
Brian.allstarglass@gmail.com
 
Drip More LLC
irene@dripmore.com
 
Godaddy.com LLC
abuse@godaddy.com
 
Shopify, Inc.
abuse@shopify.com
Back to Top